logo

For the Inventor, By the Inventor

Little Hallingbury, United Kingdom

Leslie Joseph Street

This inventor holds 70 USPTO granted patents and 4 EPO patents, primarily in GABA Receptor Inhibitors (CPC class 5143). Top assignees: Merck Sharp + Dohme Corp., Merck Sharpe & Dohme Corp.. Active years: 1991-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Leslie Joseph Street. Retrieved from https://idiyas.com/inventor/leslie-joseph-street

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 70

% Patents Active = 70.0


Average Co-Inventor Count = 4.2

ph-index = 13

Forward Citations = 716(Granted Patents)

Forward Citations (Not Self Cited) = 697(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Essex, GB (1993 - 1997)
  • Little Hallinbury, GB (2001 - 2003)
  • Harlow, GB (1991 - 2010)
  • Little Hallingbury, GB (2001 - 2010)
  • Bishops Stortford, GB (2010)
  • Newport Beach, CA (US) (2012)

Company Filing History:

goldMedal68 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
silverMedal3 out of 36 
 
Merck Sharpe & Dohme Corp.
 patents
where one patent can have more than one assignee

Years Active: 1991-2012

Loading Chart...
Loading Chart...
Areas of Expertise:
GLYT1 Transporters
Anxiolytics
Pharmaceutical Compositions
GABA Receptors
Cyclohexanesulfonyl Derivatives
Imidazo Derivatives
Triazolo Derivatives
Piperidine Derivatives
Ligands
Heteroaryl Compounds
Pyrazolo Compounds
Naphthyridines
70 patents (USPTO):Explore Patents
1. 8163956 - Inhibitors of GLYT1 transporters (2012-04-24),
2. 7851638 - Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia (2010-12-14),
3. 7825135 - Heteroaryl piperidine glycine transporter inhibitors (2010-11-02),
4. 7655644 - Piperidine and azetidine derivatives as GlyT1 inhibitors (2010-02-02),
5. 7626056 - Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia (2009-12-01),
6. 7485640 - Imidazopyrazinones as GABA-A receptor anxiolytics (2009-02-03),
7. 7176203 - Imidazo-triazine derivatives as ligands for gaba receptors (2007-02-13),
8. 7030128 - Imidazo-pyrimidine derivatives as ligands for GABA receptors (2006-04-18),
9. 7015224 - 7-Tert-butyl-3-(2-fluorophenyl)-6-(2H-(1,2,4)triazol-3-ylmethoxy)-(1,2,4)triazolo (4,3b) pyridazine for the treatment of anxiety and convulsions (2006-03-21),
10. 6969716 - 5-phenyl[1,2,4]triazines as ligands for GABA-A α2/α3 receptors for treating anxiety or depression (2005-11-29),
11. 6960598 - (1,8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses (2005-11-01),
12. 6936608 - Imidazo-triazine derivatives as ligands for GABA receptors (2005-08-30),
13. 6914065 - Imidazo[1,2-C]pyrimidine derivatives as ligands for gaba receptors (2005-07-05),
14. 6914063 - Imidazo-pyrazine derivatives as ligands for GABA receptors (2005-07-05),
15. 6900215 - Imidazo-pyrimidine derivatives as ligands for gaba receptors (2005-05-31),

Title: Leslie Joseph Street: Innovator in GLYT1 Inhibitors

Introduction: Leslie Joseph Street, a prominent inventor based in Little Hallingbury, Great Britain, has made significant contributions to the field of pharmacology with a remarkable portfolio of 70 patents. His innovative research primarily focuses on compounds that act as inhibitors of Glycine Transporter 1 (GLYT1), a crucial target in the treatment of various neurological disorders, including schizophrenia.

Latest Patents: Among his latest patents, Street has developed a compound, described by the formula (I), that serves as a GlyT1 inhibitor. This pharmaceutical composition demonstrates potential for medical application, specifically in treating schizophrenia. Another notable invention involves cyclohexanesulfonyl derivatives that also function as GLYT1 inhibitors aimed at treating schizophrenia. These compounds are characterized by various groups, such as alkyl, phenyl, heterocyclyl, and others, which enhances their therapeutic effectiveness.

Career Highlights: Street's professional journey includes notable affiliations with reputable organizations, such as Merck Sharp & Dohme Corporation and Merck Sharpe & Dohme Corp. His tenure at these prominent pharmaceutical companies has propelled advancements in medicinal chemistry and the development of new therapeutic options.

Collaborations: Throughout his career, Street has collaborated with esteemed colleagues, including William Robert Carling and Jose Luis Castro Pineiro. These partnerships have enriched his research endeavors and contributed to groundbreaking innovations in the pharmacological sector.

Conclusion: Leslie Joseph Street stands out as a trailblazer in the realm of GLYT1 inhibitors, with a substantial number of patents that showcase his ingenuity and commitment to improving medical treatments. His work continues to pave the way for advancements in therapies for conditions like schizophrenia, illustrating the vital role of inventors in the field of medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…